Summary
The durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease. This follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity. Booster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity. These findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).
Competing Interest Statement
M.F., Y.K., N.M.S., S.I., S.M., T.I., K.T., M.T., T.O., R.Y.S., T.S., M.A., A.S., and S.O. are employees of Shionogi & Co., Ltd. Y.K., N.M.S., S.I., S.M., T.I., K.T., M.T., T.O., R.Y.S., and T.S. also hold stock in Shionogi & Co., Ltd. T.I. received payment for lectures from Moderna Japan Co., Ltd. S.I. received payments or honoraria for lectures from Pfizer Japan Inc., Gilead Sciences Inc., MSD K.K., and Meiji Seika Pharma Co., Ltd., and has participated in advisory boards for Shionogi & Co., Ltd. A.K., T.T., J.K.V., and K.Y. are employees of KOTAI Biotechnologies Inc., with K.Y. also being a shareholder. T.K., X.L., R.S., S.Y., and S.O. declare no conflicts of interest.
Clinical Trial
jRCT2031210269
Funding Statement
This research is supported by Japan Agency for Medical Research and Development grant (Grant number: JP21nf0101626). This study was funded by Shionogi & Co., Ltd. Medical writing support by MedPro Clinical Research was funded by Shionogi & Co., Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in P-One Clinic Keikokai Medical Corporation in Tokyo, Japan accordance with the protocol which approved by Keikokai Medical Corporation Institutional Review Board in Tokyo, Japan, the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice Guidelines, and other applicable laws and regulations. All participants provided their written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos